Kurs
+14,38%
Likviditet
0,18 MSEK
Kalender
Tid* | ||
2025-02-26 | 08:30 | Bokslutskommuniké 2024 |
2024-11-26 | - | Kvartalsrapport 2024-Q3 |
2024-08-29 | - | Kvartalsrapport 2024-Q2 |
2024-05-10 | - | X-dag ordinarie utdelning REDS 0.00 SEK |
2024-05-08 | - | Årsstämma |
2024-05-08 | - | Kvartalsrapport 2024-Q1 |
2024-02-27 | - | Bokslutskommuniké 2023 |
2023-11-09 | - | Kvartalsrapport 2023-Q3 |
2023-08-29 | - | Kvartalsrapport 2023-Q2 |
2023-05-10 | - | X-dag ordinarie utdelning REDS 0.00 SEK |
2023-05-09 | - | Årsstämma |
2023-05-09 | - | Kvartalsrapport 2023-Q1 |
2023-02-27 | - | Bokslutskommuniké 2022 |
2022-11-09 | - | Kvartalsrapport 2022-Q3 |
2022-08-29 | - | Kvartalsrapport 2022-Q2 |
2022-05-03 | - | X-dag ordinarie utdelning REDS 0.00 SEK |
2022-05-02 | - | Årsstämma |
2022-05-02 | - | Kvartalsrapport 2022-Q1 |
2022-02-28 | - | Bokslutskommuniké 2021 |
2021-11-09 | - | Kvartalsrapport 2021-Q3 |
2021-08-24 | - | Kvartalsrapport 2021-Q2 |
2021-05-12 | - | Årsstämma |
2021-05-05 | - | X-dag ordinarie utdelning REDS 0.00 SEK |
2021-05-03 | - | Kvartalsrapport 2021-Q1 |
2021-04-19 | - | Extra Bolagsstämma 2021 |
2021-02-28 | - | Bokslutskommuniké 2020 |
2020-12-18 | - | Extra Bolagsstämma 2020 |
2020-11-09 | - | Kvartalsrapport 2020-Q3 |
2020-08-24 | - | Kvartalsrapport 2020-Q2 |
2020-06-23 | - | X-dag ordinarie utdelning REDS 0.00 SEK |
2020-06-22 | - | Årsstämma |
2020-05-04 | - | Kvartalsrapport 2020-Q1 |
2020-02-25 | - | Bokslutskommuniké 2019 |
2019-11-18 | - | Kvartalsrapport 2019-Q3 |
2019-08-26 | - | Kvartalsrapport 2019-Q2 |
2019-05-07 | - | X-dag ordinarie utdelning REDS 0.00 SEK |
2019-05-06 | - | Årsstämma |
2019-05-06 | - | Kvartalsrapport 2019-Q1 |
2019-02-26 | - | Bokslutskommuniké 2018 |
2018-08-27 | - | Kvartalsrapport 2018-Q2 |
2018-05-08 | - | X-dag ordinarie utdelning REDS 0.00 SEK |
2018-05-07 | - | Årsstämma |
2018-02-27 | - | Bokslutskommuniké 2017 |
2017-09-25 | - | Extra Bolagsstämma 2017 |
2017-08-28 | - | Kvartalsrapport 2017-Q2 |
2017-04-06 | - | X-dag ordinarie utdelning REDS 0.00 SEK |
2017-04-05 | - | Årsstämma |
2017-02-22 | - | Bokslutskommuniké 2016 |
2016-10-26 | - | Kvartalsrapport 2016-Q3 |
2016-08-25 | - | Kvartalsrapport 2016-Q2 |
2016-05-09 | - | Årsstämma |
2016-05-09 | - | Kvartalsrapport 2016-Q1 |
2016-02-23 | - | X-dag ordinarie utdelning REDS 0.00 SEK |
2016-02-22 | - | Bokslutskommuniké 2015 |
2015-11-27 | - | Kvartalsrapport 2015-Q3 |
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Medicinteknik |
Redsense Medical AB is pleased to announce that Sebastien Bollue takes over as the company's new CEO as of October 1[st], 2024. Sebastien Bollue has long and solid experience of eight years within the company and worked closely with the company's founder, Patrik Byhmer. During his time at Redsense Medical AB, Sebastien Bollue has developed a deep understanding of both the company's internal needs and the dynamics of the market. His extensive background in production, sales, marketing and business development makes him suitable to lead the company into the next phase of growth.
During his time with the company, Sebastien Bollue has demonstrated strong strategic leadership and built a broad network within the dialysis industry, which includes both customers and distributors. This network will play a decisive role in strengthening Redsense Medical AB's position on the market and drive continued profitable growth. Sebastien Bollue's ability to create close relationships with international players has already opened new opportunities for the company.
"We are convinced that Sebastien Bollue will take on the role of CEO in an excellent way. His large network in the dialysis industry, together with his solid experience in the company, will be important in leading the company to increased growth, sales and profitability," says Susanne Olauson, chairman of the board of Redsense Medical AB.
We would also like to express our warm thanks to our CFO, Jennie Kardell, who during a busy time stepped up and shouldered the role of acting CEO in an excellent way. During this period, Jennie Kardell has made a valuable contribution to the company, and we are now looking forward to having her back in her role as CFO.
Furthermore, the company's largest owner is ready to take a more active role and has announced that he is available for election to the board at the next general meeting, which further strengthens the company's future prospects and focus on growth.
For more information, please contact:
Jennie Kardell, CEO
Telephone: +46 72-171 1264
E-mail: jennie.kardell (at) redsensemedical.com
Redsense Medical AB (publ), 556646-4862